Culture

 

British Queen celebrates

image image image image
Britain shortlists 82 jobs for temporary work visas to tackle Labour shortages Read the Full Story
570,000 families dodge Hallowe’en scares with tax-free childcare Read the Full Story
Azerbaijan’s oil fund invests $66 million in London’s Gatwick Airport Read the Full Story
Macron to appoint new French Prime Minister within 48 hours Read the Full Story
* * * *

UK News

World News

Media

 

Following approval from the British health regulator for Eli Lilly's new weight-loss treatment, Health Secretary Steve Barclay expressed optimism about the potential benefits for thousands of

obese individuals in the UK. The drug, Zepbound (also known as Mounjaro or tirzepatide), received the green light from both U.S. and UK regulators, offering a formidable competitor to Novo Nordisk's Wegovy in addressing rising obesity rates.

In a statement, Barclay highlighted the drug's potential to assist people struggling with obesity and alleviate weight-related health issues when combined with proper diet and physical activity. He emphasized the impact on reducing waiting lists and potential cost savings for the National Health Service (NHS).

However, Barclay noted that additional approvals were necessary before the drug could be included in NHS coverage.